Miyama, Akira
Ebina, Kosuke http://orcid.org/0000-0002-2426-1024
Hirao, Makoto
Okamura, Gensuke
Etani, Yuki
Takami, Kenji
Goshima, Atsushi
Miura, Taihei
Oyama, Shohei
Kanamoto, Takashi
Yoshikawa, Hideki
Nakata, Ken
Article History
Received: 19 December 2020
Accepted: 8 January 2021
First Online: 9 February 2021
Compliance with ethical standards
:
: The iguratimod was kindly provided by Toyama Chemical Co., Ltd (Tokyo, Japan). K. Ebina has received research grants and lecture fee from Eisai Co., Ltd. K. Ebina and S. Oyama are affiliated with, and K. Nakata supervises the Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, which is supported by Taisho Pharmaceutical Co., Ltd. S. Oyama is an employee of Taisho Pharmaceutical Co., Ltd. These companies had no role in the study design, decision to publish, or preparation of the manuscript. A. Miyama, M. Hirao, G. Okamura, Y. Etani, K. Takami, A. Goshima, T. Miura, T. Kanamoto, and H. Yoshikawa declare that they have no conflicts of interest.